Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James P Allison

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Cancer Discovery|December 1, 2020
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic InterventionSpencer C Wei, Wouter C Meijers, Margaret L Axelrod, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
Cancer Discovery|July 23, 2017
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceAlexandre Reuben, Rachel Gittelman, Jianjun Gao, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and NeckRenata Ferrarotto, Moran Amit, Priyadharsini Nagarajan, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Nature|November 28, 2014
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigensMatthew M Gubin, Xiuli Zhang, Heiko Schuster, et al.
Cancer Discovery|December 1, 2020
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic InterventionSpencer C Wei, Wouter C Meijers, Margaret L Axelrod, et al.
Nature Communications|August 20, 2021
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancerTina Cascone, Annikka Weissferdt, Myrna C B Godoy, et al.
Cancer Immunology Research|October 30, 2019
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal ResponsesJames W Welsh, Chad Tang, Patricia de Groot, et al.
Nature Communications|October 19, 2021
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapyHussein A Abbas, Dapeng Hao, Katarzyna Tomczak, et al.
Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.
Cancer Cell|May 10, 2022
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Daniel H Johnson, Noha Abdel-Wahab, et al.
Cancer Discovery|July 23, 2017
TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical RecurrenceAlexandre Reuben, Rachel Gittelman, Jianjun Gao, et al.
Pageof 21